NCT06868992 Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA
| NCT ID | NCT06868992 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Metabolic Dysfunction-Associated Steatotic Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 20 participants |
| Start Date | 2025-04-15 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20 participants in total. It began in 2025-04-15 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main research hypothesis is that alterations in the communication between the endoplasmic reticulum (ER) and the mitochondria at contact sites called mitochondria-associated membranes (MAMs) occurs in different hepatic cell types of patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MALSD) and is involved in the progression towards MASH and could also influence the process of improvement of MASH. This study aims to investigate the link between Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Mitochondria-Associated Membranes (MAMs) in liver cells and peripheral blood mononuclear cells (PBMCs) in patients undergoing bariatric surgery. The primary objective is to analyze MAMs alterations in hepatocytes in MASH patients compared to non-MASH patients. Secondary objectives include evaluating the correlation between MAMs in PBMCs and liver cells and assessing MAMs changes post-bariatric surgery.
Eligibility Criteria
* Inclusion Criteria \* : * Female or male adult patients * Patient who has benefited from a pluridisciplinary evaluation (medical, surgical, psychiatric), with a favorable opinion for a sleeve gastrectomy or a gastric bypass. * Patient with an indication Indication for intraoperative liver biopsy due to suspected MASH * Patient who agrees to be included in the study and who signs the informed consent form, * Patient affiliated to a healthcare insurance plan. * Exclusion Criteria \* : * Patient presenting Hepatitis B as defined as presence of hepatitis B surface antigen (HBsAg). * Patient presenting previous or current infection with Hepatitis C * Autoimmune hepatitis as defined by anti-nuclear antibody (ANA) of 1:160 or greater and liver histology consistent with autoimmune hepatitis or previous response to immunosuppressive therapy. * Patient presenting Autoimmune cholestatic liver disorders as defined by elevation of alkaline phosphatase and anti-mitochondrial antibody of greater than 1:80 or liver histology consistent with primary biliary cirrhosis or elevation of alkaline phosphatase and liver histology consistent with sclerosing cholangitis. * Patient presenting Wilson disease as defined by ceruloplasmin below the limits of normal and liver histology consistent with Wilson disease. * Patient presenting Alpha-1-antitrypsin deficiency as defined by alpha-1-antitrypsin level less than normal and liver histology consistent with alpha-1-antitrypsin deficiency. * Patient presenting Hemochromatosis as defined by presence of 3+ or 4+ stainable iron on liver biopsy and homozygosity for C282Y or compound heterozygosity for C282Y/H63D. * Patient presenting Drug-induced liver disease as defined on the basis of typical exposure and history. * Patient presenting Bile duct obstruction as shown by imaging studies. * History of ingestion of medications known to produce steatosis, such as corticosteroids, high-dose estrogen, tamoxifen, methotrexate, amiodarone or tetracycline in the previous 6 months. * Evidence of cirrhosis or previously known cirrhosis based on the results from previous liver biopsy or history of portal hypertension presented by ascites, hepatic encephalopathy or varices * Consommation régulière et/ou excessive d'alcool (plus de 30g/j pour les hommes et plus de 15 g/j pour les femmes) sur une période de plus de 2 ans au cours des 10 dernières années. * History of known HIV infection * History of type 1 diabetes * Pregnant women or breastfeeding mothers\*. * Minor patient * Patient deprived of liberty, * Patients under psychiatric care * Patients admitted to a health or social care establishment for purposes other than research * Mentally unbalanced patients, under supervision or guardianship, * Patients not affiliated to a social security scheme or benefiting from a similar scheme * Patient who does not understand French/ is unable to give consent, * Patient already included in a trial who may interfere with the study
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06868992 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 99 Years, studying Metabolic Dysfunction-Associated Steatotic Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06868992 currently recruiting?
Yes, NCT06868992 is actively recruiting participants. Contact the research team at cyrielle.caussy@chu-lyon.fr for enrollment information.
Where is the NCT06868992 trial being conducted?
This trial is being conducted at Lyon, France, Pierre-Bénite, France.
Who is sponsoring the NCT06868992 clinical trial?
NCT06868992 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 20 participants.